ClinicalTrials.gg
RecruitingNCT07674004PRISMATICUpdated Jul 1, 2026

Surface-Modified Flow Diverter for Intracranial Aneurysms: Assessment of Ischemic and Clinical Outcomes

An interventional study of LFD and PED Shield in Intracranial Aneurysms and Flow Diverter, sponsored by Henan Provincial People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Henan Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 100 studies in Intracranial Aneurysm with a site in China — 38 open to participants now, 42 under way, 1 of them phase 3. Intracranial Aneurysm · China.

Planned enrollment
23rd of 49
196 · median 188
Started
2026
with 8 others
No phase
37 of 100
13 open now
Primary completion
2027-02
later than 25 of 41 live
Registered
96th of 100
by date

Among the 100 studies in Intracranial Aneurysm with a site in China, this one is the 23rd largest by planned enrollment of the 49 interventional ones that give a count, is one of 9 that started in 2026, is one of 37 with no phase, reaches primary completion later than 25 of the 41 other live ones, and was the 96th registered.

Intracranial Aneurysm

419 studies on the registry are indexed under Intracranial Aneurysm; 118 are open to participants now.

Browse Intracranial Aneurysm studies →

Open to participants now

38 of the 100 studies in Intracranial Aneurysm with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 84 Intracranial Aneurysm studies recruiting now, 50 (60%) set no upper age limit and 15 (18%) stop at 75 or younger; 16 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies in Intracranial Aneurysm with a site in China, or all of them as a file.
02

Study summary

Flow diverters (FDs) have become a mainstay of endovascular therapy for unruptured intracranial aneurysms (UIAs), yet their implantation carries an inherent risk of ischemic complications. The Pipeline Flex Embolization Device with Shield Technology (PED Shield) and the Lattice Flow Diverter (LFD) are two surface-modified FDs that have shown promising efficacy for mitigating procedure-related ischemic events in prior single-arm or retrospective series. Nevertheless, head-to-head comparative data between these two surface-modified flow diverters remain scarce, and prospective randomized clinical trials are warranted to corroborate their differential performance in lowering ischemic complication risks.This prospective, multicenter randomized controlled trial (RCT) was designed to compare the efficacy of PED Shield versus LFD in reducing ischemic complications after endovascular treatment of UIAs. A total of 196 eligible participants who meet the predefined inclusion and exclusion criteria will be enrolled in the trial. The primary outcome measure is the incidence of new diffusion-weighted imaging (DWI)-positive lesions on brain magnetic resonance imaging (MRI) within 48 hours after the procedure. The secondary outcome measures consist of perioperative symptomatic ischemic events, all-cause mortality and disability rate during the follow-up period, delayed aneurysm rupture at the 6-month follow-up, complete aneurysm occlusion rate, incidence of major in-stent stenosis (stenosis degree >50%) at the 6-month follow-up, and the number of new DWI-positive lesions within 48 hours post-procedure.

03

Conditions studied

  • Intracranial Aneurysms
  • Flow Diverter

Browse trials for

Keywords

  • intracranial aneurysms
  • flow dierters
  • surface-modified
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients were diagnosed with unruptured intracranial aneurysms, and the lesions were evaluated to be suitable for endovascular treatment with flow diverter devices (PED Shield/Lattice).
  2. During the study period, only one target aneurysm per patient was treated, with the exception of segmental lesions, in which multiple aneurysms located within the same arterial segment were treated with a single or overlapping study devices.
  3. The target aneurysm was treated solely with flow diverter (FD) implantation in the current study.
  4. The age of enrolled patients ranged from 18 to 75 years old.
  5. Patients were capable of understanding the study-related information and provided written informed consent for the use of their clinical data for research purposes.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a prior history of endovascular treatment for the target aneurysm.
  2. Patients in the acute stage of cerebrovascular diseases (acute cerebral infarction or intracerebral hemorrhage with an onset time of ≤ 2 weeks).
  3. Patients complicated with other cerebrovascular disorders, including moyamoya disease, cerebrovascular malformations, and arteriovenous fistula.
  4. Patients with atherosclerotic changes in the parent artery of the target aneurysm that necessitated additional intraoperative endovascular interventions (e.g., balloon angioplasty or conventional stent implantation).
  5. Patients with a preoperative modified Rankin Scale (mRS) score greater than 2.
  6. Patients with any absolute to device treatment as specified in the Instructions for Use (IFU).
  7. Patients enrolled in other clinical trials that may interfere with the primary or secondary endpoints of the present study.
  8. Patients with comorbidities that may interfere with neurological function evaluation, affect survival status, or impair the ability to complete follow-up visits.
  9. Pregnant or lactating female patients.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
196 participants (estimated)

Study arms

  • Active comparator
    PED Shield

    Subjects Treated with the PED Shield for Intracranial Aneurysms

    Device: PED Shield

  • Experimental
    LFD

    Subjects Treated with the LFD for Intracranial Aneurysms

    Device: LFD

Interventions

  • DeviceLFD

    Subjects who meet the inclusion and exclusion criteria will undergo randomization after signing the study informed consent form. When a subject is randomly assigned to the LFD group, the operator will implant this flow diverter following standardized surgical procedures.

  • DevicePED Shield

    Subjects who meet the inclusion and exclusion criteria will undergo randomization after signing the study informed consent form. When a subject is randomly assigned to the PED Shield group, the operator will implant this flow diverter following standardized surgical procedures.

06

What researchers measure

Primary outcomes

  1. The incidence of patients with new positive diffusion-weighted imaging (DWI) lesions

    The proportion of patients with newly developed DWI hyperintensities detected on magnetic resonance imaging (MRI) within 48 hours after the surgical procedure.

    Time frame: Within 48 Hours postoperatively.

Secondary outcomes

  1. Symptomatic neurological ischemic events

    Symptomatic neurological ischemic events related to the target aneurysm, mainly including transient ischemic attack (TIA) and acute cerebral infarction, as adjudicated by the clinical event committee.

    Time frame: 0-7 days postoperatively

  2. Mortality and major disability rate during follow-up

    Proportion of patients with a modified Rankin Scale (mRS) score \> 3 or an increase of ≥ 2 points in mRS score from baseline, as adjudicated by the clinical event committee.

    Time frame: 180 (±30) days

  3. Rate of delayed aneurysm rupture

    Incidence of intracranial hemorrhage caused by delayed rupture of the target aneurysm, as adjudicated by the clinical event committee. The time calculation starts from the first day after surgery.

    Time frame: 180 (±30) days

  4. Aneurysm complete occlusion rate

    Complete occlusion rate of the target aneurysm assessed via the Raymond-Roy classification scale.

    Time frame: 180 (±30) days

  5. Incidence of target parent artery in-stent stenosis (>50%)

    In-stent stenosis of the target parent artery was defined as stenosis degree \>50%, which was evaluated by digital subtraction angiography (DSA), computed tomography angiography (CTA), or magnetic resonance angiography (MRA) at 6 months after surgery.

    Time frame: 180 (±30) days

  6. Number of DWI positive lesions

    The number of DWI positive lesions detected on postoperative magnetic resonance imaging (MRI).

    Time frame: Within 48 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2027, 9 months after the start.

Of 59 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 134. This study's planned 9 months is below that.

Counting every sponsor, half of 106 studies reached it within 39 months; a quarter within 22 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
May 21, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Sep 30, 2027
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07674004
Lead sponsor
Henan Provincial People's Hospital
Collaborators
The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Nanyang Central Hospital, First Hospital of China Medical University, Chinese PLA General Hospital, Yichang Central People's Hospital, Shandong First Medical University, Zhujiang Hospital, Handan Central Hospital, Kaifeng Central Hospital, The First Affiliated Hospital of Zhengzhou University
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
May 21, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jul 1, 2026

Study contacts

Li Li, MD
Contact
lli120253@163.com
+8615038063905

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion